Hemophilia Treatment Market Analysis, By Key Players, Sale, Trends, Segmentation And Forecast By 2027

Date

5/25/2020 8:07:37 PM

(MENAFN- iCrowdNewsWire) May 25, 2020

The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$ 44,089.71 million by 2027.

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

Get sample PDF Report @ https://www.theinsightpartners.com/sample/TIPRE00008241/

Some of the prominent players operating in hemophilia treatment market are, Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, and Baxter International Inc. The market players are focused towards acquisitions with industry players in order to sustain their position in the market. For instance, in February 2020, Novo Nordisk launched an antihemophilic product namely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.

The hemophilia treatment market by product is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma derived coagulation factor concentrates segment held a largest market share of the hemophilia treatment market. This segment is also expected to dominate the market in 2027. The large share of plasma derived coagulation factor concentrates based hemophilia treatment can be attributed to various advantages offered by these hemophilia treatment, deep market penetration and variety of products offered by multiple players to suit diverse medical application. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest growth rate during the forecast period. Certain factors such as effectiveness of the hemophilia treatment in lesser time and better efficient blood clotting are expected to drive the segment growth.

The plasma derived coagulation factor concentrates based hemophilia treatment captured the largest share in the global hemophilia treatment market. A wide variety of hemophilia treatment is available as adjunctive measures to improve hemophilia if residual bleeding persists despite the correct application of conventional methods for hemorrhage control. Plasma-derived coagulation factor hemophilia treatment is considered to be active agents that participate in the coagulation cascade to form fibrin clots and are effective to make an intact coagulation system. Plasma is the liquid part of blood. It is pale yellow or straw-colored with proteins such as antibodies, albumin, and coagulation factors. There are several target factor drug products made from plasma proteins of human. The plasma is collected from group of people, and perform several processes to separate the plasma into its components.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in 2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

Inquiry For Discount @ https://www.theinsightpartners.com/discount/TIPRE00008241/

The report segments the global hemophilia treatment market as follows:

Global Hemophilia Treatment Market – By Product

Plasma Derived Coagulation Factor Concentrates
- Factor VIII Market
- Factor IX Market
- Factor XIII Market
- Activated Prothrombin Complex Concentrate Market
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic Agents

Global Hemophilia Treatment Market – By Disease

Hemophilia A
Hemophilia B
Hemophilia C

Global Hemophilia Treatment Market – By Treatment Type

On demand
Prophylaxis

Global Hemophilia Treatment Market – By Therapy

Replacement Therapy
ITI Therapy
Gene Therapy
Antibody Therapy

Global Hemophilia Treatment Market – By End User

Hospitals
Clinics
Ambulatory Surgical Centers
Others

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00008241/

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.